Endothelial Damage in Major Spine Surgery, Measured by Circulating Syndecan-1: an Observational Study.(GlycOrtho)

Sponsor
Istituto Ortopedico Rizzoli (Other)
Overall Status
Recruiting
CT.gov ID
NCT06119542
Collaborator
(none)
30
1
36
0.8

Study Details

Study Description

Brief Summary

The goal of this observational study is to learn about endothelial damage in major spine surgery, expressed as rise in circulating Syndecan-1.

The main questions it aims to answer are:
  • What is the extent of endothelial glycocalyx shedding in major spine surgery?

  • Are there differences in different type of surgical populations? (adolescent idiopathic scoliosis, adult degenerative spine disease, oncologic surgery)

To do so, blood samples will be drawn from participants at the following timepoints:
  • basal

  • after surgery

  • if transfusion of Fresh Frozen Plasma: before and after transfusion

  • Post-Operative Day 1-2-4

Condition or Disease Intervention/Treatment Phase

    Detailed Description

    The aim of this study is to gain information about endothelial damage in major spine surgery, expressed as shedding of glycocalyx component Syndecan-1, and subsequent rise of its plasma levels.

    This phenomenon has been extensively described in shock states (sepsis, trauma, cardiac arrest ..) but little is known about endothelial damage in elective major surgery.

    This study was designed to study the magnitude of Syndecan-1 rise after spine surgery, divided in three main categories: adolescent idiopathic scoliosis, adult degenerative and oncologic surgery.

    The investigators were also interested in the effect of Fresh Frozen Plasma transfusion on Syndecan-1 levels, since previous studies have indicated a potential benefit on endothelial integrity.

    The results of this study will be used to inform subsequent clinical trials designed to investigate the effect of different intraoperative conducts on endothelial damage.

    Study Design

    Study Type:
    Observational
    Anticipated Enrollment :
    30 participants
    Observational Model:
    Cohort
    Time Perspective:
    Prospective
    Official Title:
    Endothelial Glycocalyx Damage in Major Spine Surgery, as Measured by Circulating Syndecan-1 Levels: a Prospective Observational Pilot Study.(GlycOrtho)
    Actual Study Start Date :
    Feb 28, 2022
    Anticipated Primary Completion Date :
    Sep 30, 2024
    Anticipated Study Completion Date :
    Feb 28, 2025

    Outcome Measures

    Primary Outcome Measures

    1. Delta Syndecan-1 before -after surgery [baseline, day 1]

      Difference between basal Syndecan-1 level and level at the end of surgery

    Secondary Outcome Measures

    1. Post-Operative Syndecan-1 curve [baseline, day 1, day2, day 3, day 5]

      Variation of Syndecan-1 levels at post-operative days 1-2-4

    2. Population differences [baseline, day 1, day2, day 3, day 5]

      Difference in baseline and post-operative Syndecan-1 levels in different populations

    Other Outcome Measures

    1. Thrombomodulin [baseline, day 1, day2, day 3, day 5]

      Variations of Thrombomodulin levels

    2. Plasma effect [baseline, day 1]

      Difference in Syndecan-1 levels before and after fresh frozen plasma transfusion

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    12 Years to 75 Years
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • Undergoing Major Spine Surgery with estimated blood loss> 25% of total blood volume

    • American Society of Anesthesiology status 1-2-3

    • Able to comprehend and sign informed consent.

    • If age <18 years: parent or legal representative able to comprehend and sign informed consent

    Exclusion Criteria:
    • Surgery outside of laboratory opening hours

    • Patients undergoing spine surgery for genetic syndromes/neuromuscular scoliosis

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Sandra Giannone Bologna BO Italy 40128

    Sponsors and Collaborators

    • Istituto Ortopedico Rizzoli

    Investigators

    • Principal Investigator: Sandra Giannone, MD, Istituto Ortopedico Rizzoli

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    Responsible Party:
    Istituto Ortopedico Rizzoli
    ClinicalTrials.gov Identifier:
    NCT06119542
    Other Study ID Numbers:
    • 1064/2021/Oss/IOR
    First Posted:
    Nov 7, 2023
    Last Update Posted:
    Nov 7, 2023
    Last Verified:
    Nov 1, 2023
    Individual Participant Data (IPD) Sharing Statement:
    Undecided
    Plan to Share IPD:
    Undecided
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Keywords provided by Istituto Ortopedico Rizzoli

    Study Results

    No Results Posted as of Nov 7, 2023